UPDATE : Friday, December 13, 2019
상단여백
Samsung execs pass buck to biotech subsidiaries for destroying evidence by Jeong Sae-im 2019-10-04 11:42
Samsung Bioepis releases P3 results of Bevacizumab biosimilar in EU by Lee Han-soo 2019-09-27 11:37
‘Samsung BioLogics destroyed evidence to hide accounting fraud for months’ by Jeong Sae-im 2019-09-26 15:24
Celltrion to start marketing Herzuma in Middle East by Lee Han-soo 2019-09-26 15:02
Helixmith blames hospital for absurd drug mix-up by Jeong Sae-im 2019-09-25 13:42
라인
Court rejects Kolon’s appeal over Invossa license revocation by Jeong Sae-im 2019-09-25 11:18
FDA recommends Kolon to remanufacture Invossa’s second fluid by Jeong Sae-im 2019-09-23 15:32
Dong-A ST's Aranesp biosimilar gets nod in Japan by Lee Han-soo 2019-09-23 15:31
Biotech startups seek IPO via ‘growth potential exception’ policy by Jeong Sae-im 2019-09-17 11:26
Top court rejects financial regulator’s retry to discipline Samsung BioLogics by Jeong Sae-im 2019-09-10 14:36
라인
Canada OKs Celltrion's biosimilar by Lee Han-soo 2019-09-10 12:48
Samsung Bioepis launches Enbrel biosimilar in Brazil by Lee Han-soo 2019-09-10 12:21
Invossa victims furious at government, Kolon for ‘doing nothing’ by Jeong Sae-im 2019-09-09 15:47
Nobel laureate Honjo anticipates best combo in immunotherapies by Jeong Sae-im 2019-09-06 16:29
Change in licensing-out contract may be bad sign for Intron Biotechnology by Jeong Sae-im 2019-08-30 14:47
라인
Huons, Prestige Bio to develop biosimilars by Lee Han-soo 2019-08-28 16:05
New way found to heal wounds of autoimmune disease patients by Song Soo-youn 2019-08-28 15:19
‘GI Innovation will be small but strong leader of bioindustry’ by Kim Yun-mi 2019-08-27 15:57
Invossa victims, Kolon shareholders demand apology, compensation by Jeong Sae-im 2019-08-27 15:40
Regulator decides to delist Kolon TissueGene by Jeong Sae-im 2019-08-27 12:15
여백
여백
여백
Back to Top